Publications by authors named "Fuensanta Noguera-Perea"
Article Synopsis
- Alzheimer's disease (AD) is the leading type of dementia, affecting 35 million people globally, with the APOE ε4 allele significantly increasing the risk of late-onset AD.
- The ADAPTED consortium conducted a comprehensive analysis using various OMICS technologies to explore the effects of APOE on AD, identifying relevant genes and pathways both influenced by and independent of APOE.
- The study discovered a set of biomarkers that display contrasting profiles in plasma and brain for different AD cases, which could help develop blood tests for the disease, highlighting the effectiveness of integrating multiple OMICS data for better understanding AD.
The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD.
View Article and Find Full Text PDFBackground: In order to identify novel loci associated with Alzheimer's disease (AD), we conducted a genome-wide association study (GWAS) in the Spanish population.
Methods: We genotyped 1,128 individuals using the Affymetrix Nsp I 250K chip. A sample of 327 sporadic AD patients and 801 controls with unknown cognitive status from the Spanish general population were included in our initial study.